EN 中文
Home Strategic Partnerships News Contact us
Dry Eye Disease
Dry Eye Disease
Cyclosporine A(CsA)Ophthalmic Gel
CsA Ophthalmic Gel is an innovative drug being developed by Zhaoke Ophthalmology for the treatment of DED. It is a single daily dose hydrogel which eliminates daytime administration and the associated discomfort and inconvenience, and aims to dramatically improve patients’ treatment compliance and quality of life. It is a proprietary hydrogel with patent(s) registered in China and internationally. This novel formulation enhances the pharmacokinetic profiles of CsA on the ocular surface allowing similar efficacy to that of the Cyclosporine A products currently available for DED. However, unlike the current treatment, CsA Ophthalmic Gel’s unique formulation stays on the eye for longer, requiring only once-a-day dosing compared with traditional twice-a-day dosing, hence reducing the treatment duration.
RGN-259
RGN-259, an eye drop indicated for moderate-to-severe DED. This is a therapeutic peptide (Thymosin _x0002_4), with cellular and tissue protective as well as repair and regeneration enhancement properties. RGN-259 has a novel mechanism with dual effects of corneal repair and anti-inflammation. Studies suggest that it has fast onset efficacy in multiple outcomes of signs and symptoms. RGN-259 shows efficacy as early as 15 days after administration. Cyclosporine, a first-line DED therapy, generally shows efficacy after three to six months of use according to CIC. RGN-259 has also demonstrated an excellent safety profile in such trial.
CsA/rebamipide ophthalmic gel
An innovative combination eye gel with dual mechanisms of anti-inflammation and tear film stabilization, with potentially better efficacy for patients having inadequate response to topical CsA (estimated to account for 20% to 30% of all moderate-to-severe DED patients globally, according to CIC). In our preclinical studies, the CsA/rebamipide ophthalmic gel showed meaningful improvement in DED signs and symptoms in a rabbit DED model.
IC-265
An eye drop composed of highly selective and potent Syk tyrosine kinase inhibitor with broad anti-inflammatory effects which has also shown general efficacy in reducing signs of allergic conjunctivitis. We obtained an exclusive license from IACTA to develop, make and sell IC-265 in Greater China and certain Southeast Asia countries. Phase II clinical trial for the treatment of allergic conjunctivitis was completed.
Myopia
Myopia
NVK-002
Low concentration atropine is the only medication to date that is consistently effective in myopia progression control amongst children and adolescents. Zhaoke Ophthalmology’s innovative treatment, NVK002, is potentially the world’s first approved ophthalmic solution to control or slow myopia progression in children and adolescents. This treatment has a proprietary formulation that successfully addresses the instability of low-concentration atropine and is preservative-free with an expected shelf life of over 24 months. The clinical development of NVK002 involves two different concentrations of preservative-free atropine (0.01% and 0.02%) to determine the efficacy, safety and tolerability in children and adolescents with myopia, offering a choice for doctors and patients.
Presbyopia
Presbyopia
BRIMOCHOL™ PF and Carbachol PF
BRIMOCHOL™ PF and Carbachol PF are pupil-modulating eye drops designed to be once-daily, preservative-free therapeutics to correct for the loss of near vision associated with presbyopia. BRIMOCHOL PF is a fixed-dose combination of carbachol (a cholinergic agent) and brimonidine tartrate (an alpha-2 agonist). Carbachol PF is a proprietary, preservative-free formulation of carbachol monotherapy. Both investigational therapies reduce the size of the pupil resulting in a “pinhole effect” so that only centrally focused light rays are able to enter the eye, thereby sharpening near and intermediate images. The result is clarity of vision for near tasks like reading or using a smartphone, and intermediate tasks, such as looking at a computer screen. In the VIVID Phase 2 study, both formulations met primary and secondary endpoints, demonstrating a 3-line improvement in near visual acuity with no loss of distance vision out to nine hours. BRIMOCHOL PF and Carbachol PF were well tolerated with no serious adverse events.
wAMD
wAMD
TAB014
TAB014 is the first clinical-stage bevacizumab-based antibody indicated for wAMD in China. Bevacizumab is a clinically validated anti-VEGF drug. Globally, bevacizumab is approved for oncology treatment through intravenous infusion. However, there has been increasing offlabel use of bevacizumab via intravitreal injection for treatment of wAMD. Zhaoke Ophthalmology has obtained an exclusive license from TOT BIOPHARM to commercialize TAB014 for neovascularization-related eye diseases in China.
PAN-90806
PAN-90806 is an innovative drug indicated in the treatment of wAMD, as well as DME, the leading cause of blindness in diabetic patients worldwide. PAN-90806 is a novel eye drop formulation, decreasing the number of injections required. If approved, PAN-90806 will bring significant convenience and a less invasive treatment alternative for patients as a maintenance therapy. This will reduce the frequency of intravitreal injections and other associated treatment issues with mainstream antiVEGF therapies while at the same time maintain visual stability. PAN90806 is expected to significantly reduce treatment discontinuation, and therefore slow underlying disease progression through improved patient comfort, acceptance, convenience and compliance.
Diabetic Macular
Edema
Diabetic Macular Edema
ZK002
ZK002, a protein with a novel mechanism of action to contain inflammation (i.e., anti-inflammation effect) and vascular flood leakage (i.e., anti-permeability effect), which has potentially better efficacy advantages over existing mainstay treatments for DME. ZK002 is expected to lower treatment burden by reducing the number of intravitreal injections required and improve treatment compliance. ZK002 also has anti-angiogenesis effect in addition to anti-permeability and anti-inflammatory properties. As such, we believe ZK002 has the potential to be a foundational agent, either as monotherapy or in combination with anti-VEGF agents, to address proliferative diabetic retinopathy in addition to DME.
Also, ZK002, the protein with anti-angiogenesis and anti-inflammation effects, and therefore is an ideal drug candidate for pterygium, in which vascular angiogenesis and inflammation play prominent roles.
PAN-90806
PAN-90806 is an innovative drug indicated in the treatment of wAMD, as well as DME, the leading cause of blindness in diabetic patients worldwide. PAN-90806 is a novel eye drop formulation, decreasing the number of injections required. If approved, PAN-90806 will bring significant convenience and a less invasive treatment alternative for patients as a maintenance therapy. This will reduce the frequency of intravitreal injections and other associated treatment issues with mainstream antiVEGF therapies while at the same time maintain visual stability. PAN90806 is expected to significantly reduce treatment discontinuation, and therefore slow underlying disease progression through improved patient comfort, acceptance, convenience and compliance.
In addition to the wAMD indication, we are also developing PAN-90806 for DME.
Glaucoma
Glaucoma
Bimatoprost
Bimatoprost is a generic drug used in the treatment of glaucoma. Zhaoke Ophthalmology submitted an ANDA to the NMPA in August 2019. According to CIC, this will potentially be the first preservative-free generic drug commercialized in China, which will help improve patients’ comfort during treatment and lower the risk of patient allergies.
Levobetaxolol HCl
Levobetaxolol HCl is a generic eye drop used in the treatment of glaucoma to lower pressure in the eye. On September 2, 2021, Levobetaxolol HCl eye drops for the treatment of intraocular pressure (“IOP”) in patients with primary open-angle glaucoma or ocular hypertension has met its primary endpoint in decreasing IOP in eight weeks compared to the baseline.
Travoprost
One of the most frequently prescribed PGAs for open-angle glaucoma in China.
Bimatoprost Timolol
Bimatoprost Timolol is a potential first-to-market generic bimatoprost timolol in China targeting glaucoma. This drug is used for more advanced stages of the disease, with increased pressure in the eye.
Latanoprost Timolol
A PGA and β blocker combination eye drop targeting glaucoma.
Travoprost Timolol
A potential first-to-market generic travoprost timolol in China targeting glaucoma.
Latanoprost
One of the most frequently prescribed PGAs for open-angle glaucoma in China.

The most comprehensive product portfolio

Zhaoke Ophthalmology has a comprehensive drug portfolio of innovative and generic treatments covering six major eye diseases across both the front and back of the eye including DED, myopia, presbyopia, wAMD, DME and glaucoma. Many of the drugs are being produced in its state-of-the-art and fully functional development and production facility in Nansha, Guangzhou.
Innovative
Drugs
We have built an ophthalmic drug pipeline comprising 14 innovative drugs, including 9 drug candidates which have the potential to be market-leading products in China if approved.
Allergic conjunctivitis
Anti-infectives& anti-inflammatory,Diagnostic and Surgical use
VMT
Diabetic Macular Edema
wAMD
Myopia
Uveitis
Dry Eye Disease
Corneal Epithelial Defects
Pterygium
Presbyopia
Allergic conjunctivitis
IC-270
A fixed-dose combination of IC-265, a Syk tyrosine kinase inhibitor, and an antihistamine agent for the treatment of allergic conjunctivitis. The Syk tyrosine kinase inhibitor of IC-265 reduces redness and inflammation, and the antihistamine agent controls itching. By combining the two components, IC-270 has the potential to be a treatment for allergic conjunctivitis that addresses not only itching but also redness and inflammation associated with allergic conjunctivitis. We obtained an exclusive license from IACTA to develop, make and sell IC-270 in Greater China and certain Southeast Asia countries. We plan to commence a Phase III clinical trial in 2023 and submit an NDA to the NMPA in 2024.
Anti-infectives& anti-inflammatory,Diagnostic and Surgical use
IC-265
An eye drop composed of highly selective and potent Syk tyrosine kinase inhibitor with broad anti-inflammatory effects which has also shown general efficacy in reducing signs of allergic conjunctivitis. We obtained an exclusive license from IACTA to develop, make and sell IC-265 in Greater China and certain Southeast Asia countries. Phase II clinical trial for the treatment of allergic conjunctivitis was completed.
IC-270
A fixed-dose combination of IC-265, a Syk tyrosine kinase inhibitor, and an antihistamine agent for the treatment of allergic conjunctivitis. The Syk tyrosine kinase inhibitor of IC-265 reduces redness and inflammation, and the antihistamine agent controls itching. By combining the two components, IC-270 has the potential to be a treatment for allergic conjunctivitis that addresses not only itching but also redness and inflammation associated with allergic conjunctivitis. We obtained an exclusive license from IACTA to develop, make and sell IC-270 in Greater China and certain Southeast Asia countries. We plan to commence a Phase III clinical trial in 2023 and submit an NDA to the NMPA in 2024.
NTC010 (levofloxacin dexamethasone combination)
is an eye drop indicated for the prevention and treatment of inflammation and infection associated with cataract surgery. It is a fixed combination of levofloxacin, a quinolone antibiotic with a broad spectrum of action, at 0.5% concentration and dexamethasone, a corticosteroid anti-inflammatory agent, at 0.1% concentration. We entered into a license and supply agreement with NTC in February 2021 and obtained an exclusive license and distribution right to distribute and sell NTC010 in the PRC.
NTC014 (levofloxacin and ketorolac trometamol combination)
is an eye drop under development for the indication of moderate-to-severe bacterial conjunctivitis. It is an innovative fixed combination of levofloxacin 0.5% and ketorolac trometamol 0.5%. We obtained an exclusive license and distribution rights of NTC014 through a license and supply agreement with NTC in December 2020. We were granted an exclusive license to develop and commercialize NTC014 in Greater China, South Korea and certain Southeast Asian countries.
VMT
Resolv ER
An intravitreal injection of liposome-loaded urea for the treatment of vitreomacular traction, or VMT. Resolv ER is a urea solution encapsulated in liposomes, a type of biodegradable and biocompatible carrier that can provide sustained release for prolonged periods. By using Resolv ER, patients suffering from VMT may avoid invasive surgery and preserve vision. We obtained an exclusive license from Kato Pharmaceuticals to develop, make and sell Resolv ER in Greater China and certain countries in Southeast Asia. We plan to submit an IND application to the NMPA for in the second quarter of 2021 and initiate a Phase II clinical trial in the fourth quarter of 2021 to evaluate the safety and efficacy of Resolv ER in treating VMT.
Diabetic Macular Edema
ZK002
ZK002, a protein with a novel mechanism of action to contain inflammation (i.e., anti-inflammation effect) and vascular flood leakage (i.e., anti-permeability effect), which has potentially better efficacy advantages over existing mainstay treatments for DME. ZK002 is expected to lower treatment burden by reducing the number of intravitreal injections required and improve treatment compliance. ZK002 also has anti-angiogenesis effect in addition to anti-permeability and anti-inflammatory properties. As such, we believe ZK002 has the potential to be a foundational agent, either as monotherapy or in combination with anti-VEGF agents, to address proliferative diabetic retinopathy in addition to DME.
Also, ZK002, the protein with anti-angiogenesis and anti-inflammation effects, and therefore is an ideal drug candidate for pterygium, in which vascular angiogenesis and inflammation play prominent roles.
PAN-90806
PAN-90806 is an innovative drug indicated in the treatment of wAMD, as well as DME, the leading cause of blindness in diabetic patients worldwide. PAN-90806 is a novel eye drop formulation, decreasing the number of injections required. If approved, PAN-90806 will bring significant convenience and a less invasive treatment alternative for patients as a maintenance therapy. This will reduce the frequency of intravitreal injections and other associated treatment issues with mainstream antiVEGF therapies while at the same time maintain visual stability. PAN90806 is expected to significantly reduce treatment discontinuation, and therefore slow underlying disease progression through improved patient comfort, acceptance, convenience and compliance.
In addition to the wAMD indication, we are also developing PAN-90806 for DME.
wAMD
TAB014
TAB014 is the first clinical-stage bevacizumab-based antibody indicated for wAMD in China. Bevacizumab is a clinically validated anti-VEGF drug. Globally, bevacizumab is approved for oncology treatment through intravenous infusion. However, there has been increasing offlabel use of bevacizumab via intravitreal injection for treatment of wAMD. Zhaoke Ophthalmology has obtained an exclusive license from TOT BIOPHARM to commercialize TAB014 for neovascularization-related eye diseases in China.
PAN-90806
PAN-90806 is an innovative drug indicated in the treatment of wAMD, as well as DME, the leading cause of blindness in diabetic patients worldwide. PAN-90806 is a novel eye drop formulation, decreasing the number of injections required. If approved, PAN-90806 will bring significant convenience and a less invasive treatment alternative for patients as a maintenance therapy. This will reduce the frequency of intravitreal injections and other associated treatment issues with mainstream antiVEGF therapies while at the same time maintain visual stability. PAN90806 is expected to significantly reduce treatment discontinuation, and therefore slow underlying disease progression through improved patient comfort, acceptance, convenience and compliance.
Myopia
NVK-002
Low concentration atropine is the only medication to date that is consistently effective in myopia progression control amongst children and adolescents. Zhaoke Ophthalmology’s innovative treatment, NVK002, is potentially the world’s first approved ophthalmic solution to control or slow myopia progression in children and adolescents. This treatment has a proprietary formulation that successfully addresses the instability of low-concentration atropine and is preservative-free with an expected shelf life of over 24 months. The clinical development of NVK002 involves two different concentrations of preservative-free atropine (0.01% and 0.02%) to determine the efficacy, safety and tolerability in children and adolescents with myopia, offering a choice for doctors and patients.
Uveitis
IC-265
An eye drop composed of highly selective and potent Syk tyrosine kinase inhibitor with broad anti-inflammatory effects which has also shown general efficacy in reducing signs of allergic conjunctivitis. We obtained an exclusive license from IACTA to develop, make and sell IC-265 in Greater China and certain Southeast Asia countries. Phase II clinical trial for the treatment of allergic conjunctivitis was completed.
Dry Eye Disease
Cyclosporine A(CsA)Ophthalmic Gel
CsA Ophthalmic Gel is an innovative drug being developed by Zhaoke Ophthalmology for the treatment of DED. It is a single daily dose hydrogel which eliminates daytime administration and the associated discomfort and inconvenience, and aims to dramatically improve patients’ treatment compliance and quality of life. It is a proprietary hydrogel with patent(s) registered in China and internationally. This novel formulation enhances the pharmacokinetic profiles of CsA on the ocular surface allowing similar efficacy to that of the Cyclosporine A products currently available for DED. However, unlike the current treatment, CsA Ophthalmic Gel’s unique formulation stays on the eye for longer, requiring only once-a-day dosing compared with traditional twice-a-day dosing, hence reducing the treatment duration.
RGN-259
RGN-259, an eye drop indicated for moderate-to-severe DED. This is a therapeutic peptide (Thymosin _x0002_4), with cellular and tissue protective as well as repair and regeneration enhancement properties. RGN-259 has a novel mechanism with dual effects of corneal repair and anti-inflammation. Studies suggest that it has fast onset efficacy in multiple outcomes of signs and symptoms. RGN-259 shows efficacy as early as 15 days after administration.
Cyclosporine, a first-line DED therapy, generally shows efficacy after three to six months of use according to CIC. RGN-259 has also demonstrated an excellent safety profile in such trial.
CsA/rebamipide ophthalmic gel
An innovative combination eye gel with dual mechanisms of anti-inflammation and tear film stabilization, with potentially better efficacy for patients having inadequate response to topical CsA (estimated to account for 20% to 30% of all moderate-to-severe DED patients globally, according to CIC). In our preclinical studies, the CsA/rebamipide ophthalmic gel showed meaningful improvement in DED signs and symptoms in a rabbit DED model.
IC-265
An eye drop composed of highly selective and potent Syk tyrosine kinase inhibitor with broad anti-inflammatory effects which has also shown general efficacy in reducing signs of allergic conjunctivitis. We obtained an exclusive license from IACTA to develop, make and sell IC-265 in Greater China and certain Southeast Asia countries. Phase II clinical trial for the treatment of allergic conjunctivitis was completed.
Corneal Epithelial Defects
ZKY001
One of our Core Products and a eye drop targeting corneal epithelial defects, or CED, through anti-inflammatory effects plus stimulation of epithelial cell migration. Compared to widely prescribed growth factor therapies, such as rh-EGF and rb-bFGF drugs, which stimulate angiogenesis and may cause edema and inflammation, ZKY001 showed better in vivo efficacy in reducing corneal swelling and suppressing abnormal ocular vessel growth in preclinical animal models. ZKY001 also has a favorable safety profile, well tolerated at all concentrations in one of our Phase I clinical trials. We believe ZKY001 has the potential to be a foundational therapy for a broad range of corneal epithelial diseases.
We have completed a Phase I clinical trial for the safety,tolerabillty and systemic pharmacokinetics of ZKY001. ZKY001 was well tolerated or all concentrations during the trial. Among the 34 subjects who received ZKY001, only three mild AEs were reported, including two incidents of elevated blood triglyceride level and one incident of increased white blood cells in urine, and no subject experienced treatment-related AE.
We also completed two preclinical studies to evaluate the efficacy of ZKY001. The first study compared the efficacy of ZKY001 against rh-EGF, levofloxacin lactate and saline on the treatment of CED after laminectomy, a surgery which removes a layer in the cornea and, inevitably, creates damages to the cornea. ZKY001 showed faster onset effects than rh-EGF and levofloxacin lactate. In comparison to the saline group, the healing of the corneas treated with ZKY001 (measured by decrease in the proportion of damaged epithelial cells) reached statistical significance 24 hours after the surgery (p=0.005, p<0.05), whereas healing of the corneas treated with rh-EGF (p=0.004, p<0.05) and levofloxacin lactate (p=0.001, p<0.05) reached statistical significance on day 3 and day 4 after surgery, respectively. On day 7, corneas treated with ZKY001 were completely healed, whereas some corneas treated with levofloxacin lactate and saline remained unhealed.
The second study compared the efficacy of ZKY001 at three concentrations against rh-EGF and saline on the repair of CED after corneal alkali burns, serious damages to the cornea after contact with alkaline chemicals. The study showed that cell migration in the ZKY001 treatment groups was significantly higher than that in the control groups, with 20 μg/ml ZKY001 and 40 μg/ml ZKY001 being more efficacious than the other groups. In addition, 20 μg/ml ZKY001 and 40 μg/ml ZKY001 significantly alleviated corneal opacity and edema, which are evidence for corneal healing.
We started a Phase II clinical trial in November 2020 to evaluate the efficacy and safety of ZKY001 and expect to complete the trial in the fourth quarter of 2021. We plan to initiate a Phase III clinical trial in the second half of 2022 and target to submit an NDA to the NMPA in 2024.
Pterygium
ZK002
ZK002, a protein with a novel mechanism of action to contain inflammation (i.e., anti-inflammation effect) and vascular flood leakage (i.e., anti-permeability effect), which has potentially better efficacy advantages over existing mainstay treatments for DME. ZK002 is expected to lower treatment burden by reducing the number of intravitreal injections required and improve treatment compliance. ZK002 also has anti-angiogenesis effect in addition to anti-permeability and anti-inflammatory properties. As such, we believe ZK002 has the potential to be a foundational agent, either as monotherapy or in combination with anti-VEGF agents, to address proliferative diabetic retinopathy in addition to DME.
Also, ZK002, the protein with anti-angiogenesis and anti-inflammation effects, and therefore is an ideal drug candidate for pterygium, in which vascular angiogenesis and inflammation play prominent roles.
Presbyopia
BRIMOCHOL™ PF and Carbachol PF
BRIMOCHOL™ PF and Carbachol PF are pupil-modulating eye drops designed to be once-daily, preservative-free therapeutics to correct for the loss of near vision associated with presbyopia. BRIMOCHOL PF is a fixed-dose combination of carbachol (a cholinergic agent) and brimonidine tartrate (an alpha-2 agonist). Carbachol PF is a proprietary, preservative-free formulation of carbachol monotherapy. Both investigational therapies reduce the size of the pupil resulting in a “pinhole effect” so that only centrally focused light rays are able to enter the eye, thereby sharpening near and intermediate images. The result is clarity of vision for near tasks like reading or using a smartphone, and intermediate tasks, such as looking at a computer screen. In the VIVID Phase 2 study, both formulations met primary and secondary endpoints, demonstrating a 3-line improvement in near visual acuity with no loss of distance vision out to nine hours. BRIMOCHOL PF and Carbachol PF were well tolerated with no serious adverse events.
Allergic conjunctivitis
Anti-infectives& anti-inflammatory,Diagnostic and Surgical use
Glaucoma
Allergic conjunctivitis
Epinastine HCl
A potential first-to-market generic in China targeting allergic conjunctivitis with a dual mechanism of action of anti-histamine and mast cell stabilization. We submitted an abbreviated NDA to the NMPA in June 2020 and expect to receive approval in the first half of 2022.
Anti-infectives& anti-inflammatory,Diagnostic and Surgical use
Povidone iodine
A single-dose preservative-free eye drop for skin disinfection before and after surgery. We plan to submit an abbreviated NDA to the NMPA in the third quarter of 2021 and expect to receive approval in 2023.
Proparacaine HCl
A single-dose preservative-free proparacaine HCl eye drop for short-acting surface anesthesia. We plan to submit an abbreviated NDA to the NMPA in the fourth quarter 2021 and expect to receive approval in 2023.
Natamycin
An antifungal ophthalmic eye drop used to treat fungal infections around the eye. We plan to submit an abbreviated NDA to the NMPA in 2022 and expect to receive approval in 2024.
Fluorescein Sodium
A potential first-to-market generic in China and potentially the first fluorescein sodium in eye drop formulation. We plan to submit an abbreviated NDA to the NMPA in 2023.
Glaucoma
Bimatoprost
Bimatoprost is a generic drug used in the treatment of glaucoma. Zhaoke Ophthalmology submitted an ANDA to the NMPA in August 2019. According to CIC, this will potentially be the first preservative-free generic drug commercialized in China, which will help improve patients’ comfort during treatment and lower the risk of patient allergies.
Levobetaxolol HCl
Levobetaxolol HCl is a generic eye drop used in the treatment of glaucoma to lower pressure in the eye. On September 2, 2021, Levobetaxolol HCl eye drops for the treatment of intraocular pressure (“IOP”) in patients with primary open-angle glaucoma or ocular hypertension has met its primary endpoint in decreasing IOP in eight weeks compared to the baseline.
Travoprost
One of the most frequently prescribed PGAs for open-angle glaucoma in China.
Bimatoprost Timolol
Bimatoprost Timolol is a potential first-to-market generic bimatoprost timolol in China targeting glaucoma. This drug is used for more advanced stages of the disease, with increased pressure in the eye.
Latanoprost Timolol
A PGA and β blocker combination eye drop targeting glaucoma.
Travoprost Timolol
A potential first-to-market generic travoprost timolol in China targeting glaucoma.
Latanoprost
One of the most frequently prescribed PGAs for open-angle glaucoma in China.
Generic
Drugs
We have built an ophthalmic drug pipeline comprising 12 generic drugs including 6 potential first-to-market generics in China.
Guangzhou Headquarters
Tel: 020-39062888
E-mail: info@zkoph.com
Add: No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangzhou
Hong Kong Headquarters
Tel: (852)23145100
E-mail: info@zkoph.com
Add: Unit 716, 7/F, Building 12W Phase 3, Hong Kong Science Park Shatin, Hong Kong
Wechat
Guangzhou Headquarters
Tel: 020-39062888
E-mail: info@zkoph.com
Add: No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangzhou
Hong Kong Headquarters
Tel: (852)23145100
E-mail: info@zkoph.com
Add: Unit 716, 7/F, Building 12W Phase 3, Hong Kong Science Park Shatin, Hong Kong
Wechat